Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
Luigi Bubacco
Molecular Neurodegeneration, 2011
View PDFchevron_right
Neurodegenerative phenotypes in an A53T -synuclein transgenic mouse model are independent of LRRK2
Juan Troncoso
Human Molecular Genetics, 2012
View PDFchevron_right
α-synuclein, LRRK2 and their interplay in Parkinson’s disease
Leonardo Aliaga
Future Neurology, 2012
View PDFchevron_right
LRRK2 interactions with alpha-synuclein in Parkinson's disease brains and in cell models
Wei Gai
2013
View PDFchevron_right
LRRK2 Pharmacological Inhibition Abates α-Synuclein Induced Neurodegeneration
Hisham Abdelmotilib
The Journal of biological chemistry, 2015
View PDFchevron_right
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
Hien Thuy Tran
Molecular Therapy - Nucleic Acids, 2017
View PDFchevron_right
The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors
Jayden Lee
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2018
View PDFchevron_right
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson’s Disease
Ruth Perez, Matthew Benskey, Fredric Manfredsson
View PDFchevron_right
Leucine-Rich Repeat Kinase 2 Colocalizes with α-Synuclein in Parkinson’s Disease, but Not Tau-Containing Deposits in Tauopathies
George Perry
Neurodegenerative Diseases, 2008
View PDFchevron_right
The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo
Karine Cambon
International Journal of Molecular Sciences
View PDFchevron_right
The C-terminal fragment of LRRK2 with the G2019S substitution increases the neurotoxicity of mutant A53T α-synuclein in dopaminergic neurons in vivo
Karine Cambon
View PDFchevron_right
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α-synuclein, and tau
Jean-Marc Taymans
Bioessays, 2010
View PDFchevron_right
Central Role of α-Synuclein Oligomers in Neurodegeneration in Parkinson Disease
Alexander Kolchinsky
Archives of neurology, 2008
View PDFchevron_right
Leucine-Rich Repeat Kinase 2 Colocalizes with α-Synuclein in Parkinson’s Disease, but Not Tau-Containing Deposits in Tauopathies
Mark Smith
Neurodegenerative Diseases, 2008
View PDFchevron_right
Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease
Luis Gerardo Aguayo
Frontiers in Neuroscience, 2015
View PDFchevron_right
A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia
Wei-Hua Chiu
Acta Neuropathologica Communications
View PDFchevron_right
Faculty of 1000 evaluation for Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice
Antonio Suppa
F1000 - Post-publication peer review of the biomedical literature, 2012
View PDFchevron_right
Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death
David Sulzer
The Journal of Neuroscience
View PDFchevron_right
Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease
Diana Lázaro
Experimental Neurology, 2017
View PDFchevron_right
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity
Alicia Mansilla
Cell death & disease, 2011
View PDFchevron_right
Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease
Bernard Schneider
Biomolecules, 2015
View PDFchevron_right
α-Synuclein in Parkinson’s disease: causal or bystander?
Wolfgang Jost
Journal of Neural Transmission, 2019
View PDFchevron_right
Parkinson's disease and α-synuclein expression
Kat Gwinn
Movement Disorders, 2011
View PDFchevron_right
Expression of A53T Mutant But Not Wild-Type -Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death
David Sulzer
2001
View PDFchevron_right
The Parkinson's Disease Mutant E46K Enhances Alpha-Synuclein Phosphorylation in Mammalian Cell-Lines, in Yeast and In Vivo
Sandra Tenreiro
The Journal of biological chemistry, 2015
View PDFchevron_right
Central Role of �-Synuclein Oligomers in Neurodegeneration in Parkinson Disease
Alexander Kolchinsky
Arch Neurol, 2008
View PDFchevron_right
Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson’s disease pathogenesis
Mauro Fasano
FEBS Journal, 2010
View PDFchevron_right
High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain
Herman Van Der Putten
PLoS ONE, 2012
View PDFchevron_right
α-Synuclein Elevation in Human Neurodegenerative Diseases: Experimental, Pathogenetic, and Therapeutic Implications
Ayse Ulusoy
Molecular Neurobiology, 2013
View PDFchevron_right
Increased Levels of the Parkinson’s Disease-Associated Gene ITPKB Correlate with Higher Expression Levels of α-Synuclein, Independent of Mutation Status
Alexandros A Lavdas
International Journal of Molecular Sciences
View PDFchevron_right
Modification of α-Synuclein by Phosphorylation: A Pivotal Event in the Cellular Pathogenesis of Parkinson’s Disease
kavina ganapathy
Protein Phosphorylation, 2017
View PDFchevron_right
A new synuclein-transgenic mouse model for early Parkinson’s reveals molecular features of preclinical disease
Nathalie Nicot
View PDFchevron_right
α-Synuclein Lowers p53-dependent Apoptotic Response of Neuronal Cells
cristine Alves da Costa
Journal of Biological Chemistry, 2002
View PDFchevron_right